Altru is pleased to announce treatment of the first patient with a new renal  denervation (RDN) procedure, now offered for certain patients with high blood pressure.  Approved by the U.S. Food and Drug Administration (FDA) in November 2023, the renal  denervation (RDN) system involves a minimally invasive procedure that targets nerves near the  kidneys that can become overactive and cause high blood pressure. The procedure – also  known as the blood pressure procedure - is approved for use as an adjunctive treatment in  patients with high blood pressure (or hypertension) when lifestyle changes and antihypertensive  medications do not adequately control blood pressure.